WebResults from the randomized international phase III HIMALAYA trial showed that a combination of durvalumab (Imfinzi) plus the experimental drug tremelimumab, both … Web4 ago 2024 · The results of the Phase III IMbrave150 and HIMALAYA trials suggest that Atezo/Bev is generally the first choice of first-line treatment. However, when Atezo/Bev becomes PD, combination therapy with durvalumab and tremelimumab, which have different modes of action, may be indicated as second-line therapy.

FDA Grants Priority Review to Tremelimumab for Unresectable HCC

Web6 giu 2024 · of durvalumab every 4 weeks, 75mg of tremelimumab every 4 weeks for four doses plus 1500mg of durvalumab every 4 weeks (a regimen termed T751D), or 400mg … Web31 gen 2024 · Richard D. Kim, MD, Moffitt Cancer Center, Tampa, FL, discusses the results of HIMALAYA, (NCT03298451), an open-label, randomized, multicenter, Phase III stu... infect ou infecte

Dual Immunotherapy Makes Strides against HCC - PubMed

Web27 gen 2024 · This was a randomised, open-label, multicenter study of tremelimumab and durvalumab as first-line therapy in patients with unresectable hepatocellular carcinoma (uHCC). Initially, he discusses the background and methodology of the study. Dr Abou-Alfa then talks about the results from this trial. He says that HIMALAYA was the first large … WebHIMALAYA (NCT03298451) evaluated the efficacy and safety of STRIDE or D vs sorafenib (S) in uHCC. Methods: HIMALAYA is an open-label, multicenter, phase 3 study, in which pts with uHCC and no prior systemic therapy were initially randomized to STRIDE (T 300 mg plus D 1500 mg [one dose] plus D 1500 mg every 4 weeks [Q4W]), D (1500 mg Q4W), S … WebRichard D. Kim, MD, Moffitt Cancer Center, Tampa, FL, discusses the results of HIMALAYA, (NCT03298451), an open-label, randomized, multicenter, Phase III stu... infect other term